$フォグホーン セラピューティクス(FHTX.US)$Foghorn Therapeutics Inc. is set to share updates on its cancer research pipeline during a conference call and webcast on April 9, 2024, coinciding with the AACR Annual Meeting. The company will outline progress in its preclinical trials, including the development of promising new inhibitors and degraders, with the intention of engaging with investors about these advancements. These forward-looking statements, while offering insights into potential...
$フォグホーン セラピューティクス(FHTX.US)$ NEWS Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
Foghorn Therapeutics' revenue estimates downgraded by analysts, expected losses per share increased. The company's slower growth compared to industry peers could be a concern for shareholders.
Foghorn Therapeutics' low P/S ratio may be due to investor skepticism about sustained strong revenue. The company's forecasted growth, lower than the industry average, could be causing shareholder unease and potentially impeding a strong share price rise.
$フォグホーン セラピューティクス(FHTX.US)$Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor GlobeNewswire· 7 mins ago CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- FoghornTherapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development. Lilly plan...
フォグホーン セラピューティクスに関するコメント
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
GlobeNewswire· 7 mins ago
CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- FoghornTherapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development. Lilly plan...
まだコメントはありません